ENVB · Enveric Biosciences, Inc. · Executive Compensation
$1.52
+0.03 (+2.01%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.80M
Shares
4.48M
Volume · Nov 12
32.25K
Avg daily vol (3M)
71.41K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | Chief Executive Officer | $879,541 |
| Kevin Coveney | Chief Financial Officer | $678,445 |
| Peter Facchini | Chief Innovation Officer | $253,172 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | Chief Executive Officer | $611,533 |
| Kevin Coveney | Chief Financial Officer | $478,002 |
| Peter Facchini | Chief Innovation Officer | $274,580 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | Chief Executive Officer | $577,094 |
| Kevin Coveney | Chief Financial Officer | $358,677 |
| Peter Facchini | Chief Innovation Officer | $282,091 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Avani Kanubaddi | Former President and Chief Operating Officer ^^ | $1,300,597 |
| Joseph Tucker | Chief Executive Officer ^^ | $825,937 |
| Peter Facchini | Chief Innovation Officer ^^ | $332,375 |
| Kevin Coveney | Chief Financial Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Avani Kanubaddi | Former President and Chief Operating Officer ^^ | $4,236,593 |
| Peter Facchini | Chief Innovation Officer | $1,704,608 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Joseph Tucker, Ph.D. | director | Appointed | 2023-11-02 |
| Marcus Schabacker, M.D., Ph.D. | director | Appointed | 2023-11-02 |
| George Kegler | director | Appointed | 2023-11-02 |
| Frank Pasqualone | director | Appointed | 2023-11-02 |
| Michael D. Webb | director | Appointed | 2023-11-02 |
| Avani Kanubaddi | President and Chief Operating Officer | Terminated | 2023-05-24 |
| Kevin Coveney | Chief Financial Officer | Appointed | 2023-02-28 |
| Robert Dickey IV | chief financial officer | Resigned | 2023-02-28 |
| Kevin M. Coveney | chief financial officer | Appointed | 2023-02-28 |
| Robert Dickey IV | Chief Financial Officer ("CFO") | Appointed | 2022-09-13 |
| Frank Pasqualone | director of the Board | Appointed | 2022-07-18 |
Leadership
- David Johnson CEO, Board Member
- Dr. Joseph Tucker CEO, Board Member
- Joseph Tucker CEO, Board Member
- Dave Johnson Chairman
- Michael D. Webb Chairman, Board Member
- Michael Webb Chairman, Board Member
- Carter J. Ward CFO
- John Van Buiten CFO
- Kevin Coveney CFO
- Kevin M. Coveney CFO
- Robert Dickey IV CFO
- Dr. Jillian Hagel CTO
- Brad Thompson Board Member
- Douglas Lind, M.D. Board Member
- Dr. Doug Lind Board Member
- Dr. Marcus Schabacker Board Member
- Frank Pasqualone Board Member
- George Kegler Board Member
- Joseph Tucker, Ph.D. Board Member
- Marcus Schabacker Board Member
- Marcus Schabacker, M.D., Ph.D. Board Member
- Mike Webb Board Member
- Sheila DeWitt Board Member
- Sheila DeWitt, Ph.D Board Member
- Sol Mayer Board Member
- Sol Myer Board Member
Key facts
CIK
890821
CUSIP
29405E505
13F (30d)
16 filings
12 filers
Visit website
Investor relations